Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

TCT 2023 crowd

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

With a growing shortage of cardiologists in the U.S., there is growing interest recruiting more clinicians from overseas. But there are barriers to this, approach explained Abdel Almanfi, MD, FACC, FSCAI, a structural heart interventional cardiologist at Baylor St. Luke's Medical Center in Houston, Texas. He spoke with Cardiovascular Business and shared his journey from Libya to the United States, shedding light on the challenges foreign doctors face in realizing their dreams of practicing in America.

Cardiologist shares his long journey from Libya to United States

Abdel Almanfi, MD, went through years of training in Libya, but then he had to start over once he landed in the United States. 

Boston Scientific’s Agent Drug-Coated Balloon (DCB), which delivers a therapeutic dose of the anti-proliferative drug paclitaxel to the patient’s scar tissue to prevent ISR from recurring, gained FDA approval on March 1..

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

Carrie Redick RN MSN NEA-BC, director of interventional cardiology and structural heart, Morristown Medical Center, Atlantic Health System, explains the need for financial literacy among structural heart program directors at the Transcatheter Cardiovascular therapeutics (TCT) 2023 meeting.

Why financial literacy is so important for structural heart program directors

Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary. 

Video of Patricia Keegan, NP, Emory, explains value of the ACC TVT NCDR registry for TAVR and why it is important from both a quality monitoring standpoint and for attracting patients to your program.

Data registries have been a huge success for U.S. structural heart programs

ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.

CroíValve DUO device tricuspid valve

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board

The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation. 

Samin Sharma, MD, director of interventional cardiology and director of clinical cardiology, Mount Sinai Hospital, New York, discusses the first-in-human use of the Magenta Elevate percutaneous left ventricular assist device (pLVAD) with a small 10 French size and 5.5 liters per minute of hemodynamic support.

Initial results promising for world's smallest percutaneous heart pump

A new 10 French percutaneous heart pump could help greatly reduce vascular complications and improve cardiogenic shock outcomes.

Video of Yousif Ahmad, MD, Yale, discussing IVL advances and increased reinbursements

Tracking key advances in intravascular lithotripsy

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup